Print
Jul 18, 2019
Business Insider - Markets Insider
PRESS RELEASE
Trefoil Therapeutics, a private biotechnology company, raised $28 million to develop novel engineered fibroblast growth factor-1 proteins as a therapy to treat serious corneal endothelial diseases and epithelial disorders. The technology underlying Trefoil’s platform was developed by co-founder Michael Blaber, Ph.D., and is licensed from Florida State University.